Johnson & Johnson (NYSE:JNJ) Shares Acquired by Rossmore Private Capital

Share on StockTwits

Rossmore Private Capital boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 1.1% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 58,112 shares of the company’s stock after purchasing an additional 645 shares during the quarter. Johnson & Johnson accounts for about 2.9% of Rossmore Private Capital’s portfolio, making the stock its 5th largest holding. Rossmore Private Capital’s holdings in Johnson & Johnson were worth $8,094,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Fisher Asset Management LLC increased its holdings in Johnson & Johnson by 2.6% in the 2nd quarter. Fisher Asset Management LLC now owns 11,841,121 shares of the company’s stock valued at $1,649,231,000 after buying an additional 301,124 shares during the period. Clearbridge Investments LLC increased its holdings in Johnson & Johnson by 0.5% in the 1st quarter. Clearbridge Investments LLC now owns 9,628,443 shares of the company’s stock valued at $1,345,960,000 after buying an additional 48,582 shares during the period. Nordea Investment Management AB increased its holdings in Johnson & Johnson by 14.2% in the 1st quarter. Nordea Investment Management AB now owns 8,709,414 shares of the company’s stock valued at $1,217,494,000 after buying an additional 1,079,751 shares during the period. Thoroughbred Financial Services LLC increased its holdings in Johnson & Johnson by 14,147.0% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 4,014,247 shares of the company’s stock valued at $401,425,000 after buying an additional 3,986,071 shares during the period. Finally, Swedbank increased its holdings in Johnson & Johnson by 5.5% in the 4th quarter. Swedbank now owns 4,001,754 shares of the company’s stock valued at $509,303,000 after buying an additional 209,665 shares during the period. Institutional investors and hedge funds own 67.23% of the company’s stock.

Shares of Johnson & Johnson stock traded down $1.02 during midday trading on Wednesday, hitting $128.62. 30,426 shares of the company traded hands, compared to its average volume of 7,262,639. The stock has a market cap of $337.10 billion, a price-to-earnings ratio of 15.72, a PEG ratio of 2.16 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.04 and a current ratio of 1.33. The firm’s fifty day moving average price is $131.66 and its 200-day moving average price is $136.44. Johnson & Johnson has a 12 month low of $121.00 and a 12 month high of $148.99.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.42 by $0.16. The company had revenue of $20.56 billion for the quarter, compared to analyst estimates of $20.39 billion. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The firm’s revenue was down 1.3% on a year-over-year basis. During the same period in the previous year, the firm posted $2.10 EPS. Equities research analysts forecast that Johnson & Johnson will post 8.6 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be issued a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a dividend yield of 2.95%. The ex-dividend date is Monday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.45%.

In other Johnson & Johnson news, Director Marillyn A. Hewson bought 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 11th. The shares were acquired at an average cost of $139.68 per share, for a total transaction of $419,040.00. Following the transaction, the director now directly owns 3,000 shares in the company, valued at $419,040. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.23% of the stock is owned by company insiders.

Several equities analysts have commented on the stock. Zacks Investment Research lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 target price on the stock. in a report on Thursday, July 18th. Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, July 16th. Bank of America reaffirmed a “hold” rating and set a $150.00 price target on shares of Johnson & Johnson in a report on Tuesday, July 16th. Raymond James decreased their price target on shares of Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating on the stock in a report on Wednesday, July 17th. Finally, Barclays initiated coverage on shares of Johnson & Johnson in a report on Friday, June 21st. They set a “hold” rating and a $140.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $150.60.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: Momentum Investing

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Retail Opportunity Investments  Raised to “Hold” at Zacks Investment Research
Retail Opportunity Investments Raised to “Hold” at Zacks Investment Research
Morgan Stanley Cuts Zillow Group  Price Target to $32.00
Morgan Stanley Cuts Zillow Group Price Target to $32.00
BT Group – CLASS A  Receives Average Recommendation of “Buy” from Analysts
BT Group – CLASS A Receives Average Recommendation of “Buy” from Analysts
Ascendis Pharma A/S  Expected to Announce Quarterly Sales of $1.88 Million
Ascendis Pharma A/S Expected to Announce Quarterly Sales of $1.88 Million
Superloop  Trading Down 3.4%
Superloop Trading Down 3.4%
Vegalab  Shares Up 2.9%
Vegalab Shares Up 2.9%


© 2006-2019 Ticker Report